PATENT CLAIM ANALYSIS

Application Number: 15948036
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-03
Patent Classification: ["536", "023100"]

Abstract:
Disclosed are short DNA aptamers that selectively recognize CD200R1, a protein expressed on the surface of myeloid and lymphoid cells that delivers immune inhibitory signals to modulate inflammation when engaged with its ligand, CD200. Also disclosed is the use of said aptamers as therapeutic agents, for the purpose of decreasing inflammatory response; treatment of spinal cord injury; treatment of an immune related disease such as arthritis, asthma, allergy, infection; as a course of treatment during or after transplantation; or for treatment of an autoimmune disorder such as systemic lupus erythematosus, Parkinson's Disease, or multiple sclerosis.

Claim (Index 16):
The pharmaceutical composition of  claim 15  wherein the aptamer or oligonucleotide is a pegylated CCS13.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 91.0
- Lexical Diversity: 1.44737
- Patent Class: 536.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15127909', '10477525', '15500345', '10829504', '14413727']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6055327812508082
- 35 USC 102 Novelty (BERT): 0.6533458486790893
- Combined Prediction Score: 0.6103140879936363
- Mean Citation Score: 348.690516
- Max Citation Score: 751.4685
- Similarity Product: 584.9377532077432

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test